Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.

Within three years, the project anticipates at least one test for the early-stage detection of Alzheimer's disease could be ready for commercialization.

The Cambridge, UK-based firm said that the project will help it to develop its breath-based tests and support the development of tools for breath-based testing.

NEW YORK – German digital pathology company Mindpeak announced Monday that it has raised $15.3 million in a Series A financing round.

The deal comes on the heels of a similar arrangement Nanostics struck with Protean BioDiagnostics for the US market.

The University of Maryland spinout said it plans to launch a point-of-care urinary tract infection test by 2025, followed by three more tests by 2028.

According to the government, Rashid Naqvi, a Houston-area resident, fraudulently sought $4.6 million from Medicare for COVID-19 test kits and obtained $2.0 million.

Lab test reimbursement cuts and price reporting requirements that were called for under the law will be delayed as part of the recently passed spending bill.

MDxHealth also said a strategic partner is purchasing 1,500,000 ordinary shares in the offering directly from the company rather than through the underwriters.